CID HoldCo, Inc. — Form 8-K Summary
Reporting date: September 25, 2026 (filed September 29, 2026). The filing reports a definitive agreement to acquire Envoy Technologies, Inc.; it does not announce that the acquisition has closed.
Business context and transaction
CID HoldCo entered into a Securities Purchase Agreement with BladeRanger Ltd. and Envoy to acquire 100% of Envoy’s outstanding capital stock. The agreement supersedes a September 14 term sheet. The filing describes the transaction in the context of residential, hospitality and campus shared electric-vehicle mobility markets.
At closing, CID HoldCo expects to issue 10,833,333 shares valued at $65 million using a $6.00 reference price: 233,543 common shares and 8,433,123 Series C preferred shares to BladeRanger, plus 2,166,667 Series C preferred shares to Envoy’s $12.5 million convertible-note holder if that holder joins the agreement and satisfies the related conditions.
Key financial and security terms
- The Series C preferred has a $6.00 stated value, is generally non-voting, and is convertible one-for-one into common stock. Before stockholder approval, conversion is subject to a 19.99% beneficial-ownership blocker. Upon approval, the blocker ends and outstanding Series C shares automatically convert. The preferred has a liquidation preference equal to the greater of stated value or as-converted value and is not redeemable.
- BladeRanger may receive additional shares at $6.00 per share for specified amounts it funds or pays through closing. Envoy-related amounts are capped at $500,000; no more than 400,000 Series C shares may be issued for specified Company-related amounts. If BladeRanger discharges more than $1.6 million of Company debt, the excess is reimbursable in cash at closing.
- After closing and before stockholder approval, the Company must provide Envoy with net proceeds exceeding $2.0 million from specified capital-raising transactions.
- The Company will assume BladeRanger’s backstop obligation for certain Envoy vehicle leases, described as approximately $700,000, and is to provide a letter of credit within 30 days after closing. The Company must pursue releases of BladeRanger and the noteholder from the related guarantees and indemnify them until release.
- The filing provides no current revenue, earnings, cash-flow, margin, debt, or liquidity metrics for the Company or Envoy, and no comparable-period financial results. It therefore does not allow an assessment of operating performance or pro forma financial impact.
Timing, governance and other terms
- Closing is targeted for October 6, 2026, subject to customary conditions, including required Israeli and Tel Aviv Stock Exchange approvals, conversion of Envoy’s note, and the noteholder’s joinder and transfer of its Envoy shares. The Company’s obligation to close also depends on the absence of an Envoy material adverse effect.
- Stockholder approval is required under Nasdaq rules for specified change-of-control and share issuances, but is not a closing condition. The parties must use reasonable best efforts to obtain approval by January 31, 2027.
- BladeRanger may designate one director and, while it retains that board-designation right, one executive-management member. The board is to remain at seven directors, including four independent directors. The agreement also provides a three-year non-compete in specified U.S. markets.
- BladeRanger’s common shares received upon conversion of its Series C are subject to a lock-up ending on the earlier of April 1, 2027 or six months after conversion, followed by sale limits. The noteholder’s converted shares are subject to a 12-month lock-up, with a stated distribution carve-out.
- Specified indemnification claims have a $100,000 deductible; pre-closing liabilities have a $250,000 cap; and other general indemnification is generally capped at 25% of the Envoy-side shares’ $65 million reference value, subject to exceptions. BladeRanger’s capped post-closing indemnification is generally payable only in its shares, except for fraud.
Outlook, risks and unusual items
The transaction remains conditional, and the filing gives no assurance it will close. The noteholder’s joinder, note conversion and share transfer are conditions to the Company’s obligation to consummate the acquisition; unless the holder joins, it has no rights to transaction consideration under the agreement. Other disclosed risks include potential transaction costs, litigation, management distraction, effects on personnel and business relationships, going-concern uncertainty, and the Company’s ability to maintain its Nasdaq listing. The filing also describes interim anti-dilution protections for BladeRanger, subject to specified exceptions.
Important facts for investors to verify
- Whether all closing conditions are met or waived, and whether the acquisition closes on the targeted timetable.
- Whether the noteholder executes the joinder, converts the $12.5 million note, and transfers the resulting Envoy shares.
- The final shares issued, including any additional BladeRanger-funded amounts, and any cash reimbursement for Company debt discharged above $1.6 million.
- The proxy statement’s transaction details, required stockholder vote, and the effects of the 19.99% conversion blocker and subsequent automatic conversion.
- Envoy’s Rule 3-05 financial statements and the Company’s forthcoming financial disclosures, including the effect of the acquisition and assumed lease-related obligations on liquidity and capital needs.
- Progress on the approximately $700,000 lease backstop, letter of credit, and releases of existing guarantors.